title: Mapping the agonist binding site of the nicotinic acetylcholine receptor. Orientation requirements for activation by covalent agonist.
abstract: To characterize the structural requirements for ligand orientation compatible with activation of the Torpedo nicotinic acetylcholine receptor (nAChR), we used Cys mutagenesis in conjunction with sulfhydryl-reactive reagents to tether primary or quaternary amines at defined positions within the agonist binding site of nAChRs containing mutant alpha- or gamma-subunits expressed in Xenopus oocytes. 4-(N-Maleimido)benzyltrimethylammonium and 2-aminoethylmethanethiosulfonate acted as irreversible antagonists when tethered at alphaY93C, alphaY198C, or gammaE57C, as well as at alphaN94C (2-aminoethylmethanethiosulfonate only). [2-(Trimethylammonium)-ethyl]-methanethiosulfonate (MTSET), which attaches thiocholine to binding site Cys, also acted as an irreversible antagonist when tethered at alphaY93C, alphaN94C, or gammaE57C. However, MTSET modification of alphaY198C resulted in prolonged activation of the nAChR not reversible by washing but inhibitable by subsequent exposure to non-competitive antagonists. Modification of alphaY198C (or any of the other positions tested) by [(trimethylammonium)methyl]methanethiosulfonate resulted only in irreversible inhibition, while modification of alphaY198C by [3-(trimethylammonium)propyl]methanethiosulfonate resulted in irreversible activation of nAChR, but at lower efficacy than by MTSET. Thus changing the length of the tethering arm by less than 1 A in either direction markedly effects the ability of the covalent trimethylammonium to activate the nAChR, and agonist activation depends on a very selective orientation of the quaternary ammonium within the agonist binding site.
authors.affiliation: Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: D A
authors.initials: DA
authors.lastname: Sullivan
authors.forename: J B
authors.initials: JB
authors.lastname: Cohen
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000345:Affinity Labels / Q000494:pharmacology; D000478:Alkylation; D000818:Animals; D001665:Binding Sites; D003545:Cysteine / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D005020:Ethyl Methanesulfonate / Q000031:analogs & derivatives / Q000494:pharmacology; D007202:Indicators and Reagents / Q000494:pharmacology; D007700:Kinetics; D008698:Mesylates / Q000494:pharmacology; D008956:Models, Chemical; D016296:Mutagenesis; D018722:Nicotinic Agonists / Q000737:chemistry*; D018408:Patch-Clamp Techniques; D020836:Protein Structure, Quaternary; D000644:Quaternary Ammonium Compounds / Q000378:metabolism / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000737:chemistry*; D013997:Time Factors; D014158:Transcription, Genetic; D014981:Xenopus / Q000196:embryology
chemical_list: D000345:Affinity Labels; D007202:Indicators and Reagents; D008698:Mesylates; D018722:Nicotinic Agonists; D000644:Quaternary Ammonium Compounds; D011978:Receptors, Nicotinic; C093171:methanethiosulfonate ethylammonium; C109154:(2-(trimethylammonium)ethyl)methanethiosulfonate; C008313:4-(N-maleimido)benzyltrimethylammonium; D005020:Ethyl Methanesulfonate; D003545:Cysteine; D000109:Acetylcholine